留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

阿瑞匹坦对乳腺癌AC方案化疗后中重度呕吐患者的二级预防

齐婧

downloadPDF
文章导航 > 药学实践与服务  > 2017 >  35(2): 158-160,181
齐婧. 阿瑞匹坦对乳腺癌AC方案化疗后中重度呕吐患者的二级预防[J]. 药学实践与服务, 2017, 35(2): 158-160,181. doi: 10.3969/j.issn.1006-0111.2017.02.015
引用本文: 齐婧. 阿瑞匹坦对乳腺癌AC方案化疗后中重度呕吐患者的二级预防[J]. 药学实践与服务, 2017, 35(2): 158-160,181. doi: 10.3969/j.issn.1006-0111.2017.02.015
shu
QI Jing. The secondary prevention of aprepitant in moderate-severe vomiting caused by AC chemotherapy on breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 158-160,181. doi: 10.3969/j.issn.1006-0111.2017.02.015
Citation: QI Jing. The secondary prevention of aprepitant in moderate-severe vomiting caused by AC chemotherapy on breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 158-160,181. doi: 10.3969/j.issn.1006-0111.2017.02.015
shu

阿瑞匹坦对乳腺癌AC方案化疗后中重度呕吐患者的二级预防

doi: 10.3969/j.issn.1006-0111.2017.02.015

  • 滨州医学院, 山东 烟台 264003;山东省德州市市立医院肿瘤科, 山东 德州 253000

The secondary prevention of aprepitant in moderate-severe vomiting caused by AC chemotherapy on breast cancer

  • Binzhou Medical University, Yantai 264003, China;Oncology Department, Dezhou Municipal Hospital, Dezhou 253000, China

  • 摘要: 目的 观察分析联合应用阿瑞匹坦、盐酸托烷司琼、地塞米松二级预防乳腺癌术后蒽环类药物联合环磷酰胺（AC方案）化疗所致恶心呕吐的疗效及不良反应。 方法 选取2015年1月至2016年5月在山东省德州市市立医院肿瘤科住院治疗的乳腺癌术后AC方案首次化疗相关性恶心呕吐（chemotherapy-induced nausea and vomiting，CINV）为中重度的患者72例，随机分为观察组35例，对照组37例。继续化疗过程中，观察组使用阿瑞匹坦+盐酸托烷司琼+地塞米松三联止吐药物预防CINV，对照组使用盐酸托烷司琼+地塞米松预防CINV。观察两组患者化疗后急性期（0~24 h）及延迟期（24~120 h）预防恶心呕吐的效果及不良反应发生情况。 结果 两组患者急性期呕吐的完全控制率比较，差异无统计学意义（P>0.05），观察组急性期呕吐的有效控制率较对照组明显升高，差异有统计学意义（P<0.05）；观察组延迟期呕吐的完全控制率及有效控制率均高于对照组，差异均有统计学意义（P<0.05）。两组患者不良反应主要为便秘、疲乏、面色潮红、焦虑及头晕等，均症状轻微。 结论 对乳腺癌AC方案化疗后中重度呕吐患者，化疗过程中给予阿瑞匹坦三联止吐治疗效果好，经济效益较高，且不良反应轻微，患者可耐受。
    Abstract: Objective To evaluate the efficacy and side effects of combination therapy with aprepitant, tropisetron and dexamethasone in the prevention of nausea and vomiting induced by AC chemotherapy in patients after breast cancer surgery. Methods 72 breast cancer patients were selected for this study. Those patients were admitted to the Oncology Department in Dezhou Municipal Hospital from January 2015 to May 2016. The patients were randomly divided into observation group (35 cases) and control group (37 cases). All patients underwent breast cancer surgery and followed by AC program for the first time chemotherapy. Chemotherapy induced nausea and vomiting (CINV) were rated moderate to severe during the course of chemotherapy. The patients in the observation group were treated with aprepitant, tropisetron hydrochloride and dexamethasone to prevent CINV. The control group was treated with tropisetron hydrochloride and dexamethasone. The efficacy and adverse reactions in acute phase (0~24 h) and delay phase (24~120 h) were recorded. Results There was no significant difference in the complete control rate (CR) between the two groups during acute phase (P>0.05). The observation group had significantly higher effective control rate (CR+PR) in acute phase compared to the control group (P<0.05). Both CR and CR+PR were statistically higher in observation group during delay phase (P<0.05). The main adverse reactions in two groups were constipation, fatigue, facial flushing, anxiety and dizziness. Those side effects are considered as mild and tolerable. Conclusion Triple antiemetic therapy including aprepitant has good efficacy and reasonable cost to effect ratio for patients received AC chemotherapy after breast cancer surgery with moderate-severe vomiting. This treatment is easy to accept for those patients.
  • [1] Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics[J]. Cancer, 2004, 100(10):2261-2268.
    [2] 余华琴,陈华英,任若梅,等. 阿瑞匹坦三联止吐方案用于接受高致吐方案化疗患者的疗效观察[J]. 现代中西医结合杂志,2016,25(3):274-276.
    [3] 田奕,王平,马丽君.应用R-INVR国际量表评估阿瑞匹坦、欧赛、地塞米松对于乳腺癌患者化疗所致中重度呕吐治疗效果观察[J]. 中国现代医学杂志,2016,26(18):136-139.
    [4] Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting[J]. Cancer Invest, 2000, 18(2):163-173.
    [5] 于莉,张晓晔.阿瑞匹坦在实体肿瘤化疗止吐治疗的研究进展[J]. 中国肿瘤临床与康复,2016,23(9):1148-1152.
    [6] Aapro M, Carides A, Rapoport BL, et al. Aprepitant and fosaprepitant:a 10-year review of efficacy and safety[J]. Oncnlogist, 2015, 20(4):450-458.
    [7] 郑琪,廖子君,李旭,等. 阿瑞匹坦治疗化疗诱导的爆发性恶心呕吐的临床观察[J]. 山西医科大学学报,2016,47(6):539-543.
    [8] Chu CC, Hsing CH, Shieh JP, et al. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting[J]. Eur J Pharmacol, 2014, 722:48-54.
    [9] 丁荣楣,王平,田奕,等. 阿瑞匹坦辅助预防乳腺癌FAC方案化疗致恶心呕吐的临床观察[J]. 疑难病杂志,2015,14(1):45-48.
  • [1] 毛智毅, 王筱燕, 陈晓颖, 汤逸斐.  度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
    [2] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [3] 练鲁英, 刘盈, 殷佳, 诸国樑, 徐飞.  上海某三级公立医院药品管理内部控制评价实践研究 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202402003
    [4] 崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺.  临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
    [5] 陈怡君, 王卓, 何苗, 张宇, 田泾.  泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
    [6] 杨凤艳, 张月, 陈恩贤, 缪雪蓉, 魏凯.  瑞马唑仑临床应用研究进展 . 药学实践与服务, 2024, 42(9): 365-374. doi: 10.12206/j.issn.2097-2024.202405026
    [7] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
    [8] 戴菲菲, 傅翔, 陈琼年, 俞苏纯.  上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
    [9] 冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军.  雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3580
  • HTML全文浏览量:  431
  • PDF下载量:  426
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-12-01
  • 修回日期:  2017-03-01

阿瑞匹坦对乳腺癌AC方案化疗后中重度呕吐患者的二级预防

doi: 10.3969/j.issn.1006-0111.2017.02.015
  • 滨州医学院, 山东 烟台 264003;山东省德州市市立医院肿瘤科, 山东 德州 253000
  • 收稿日期: 2016-12-01
  • 修回日期: 2017-03-01

摘要: 目的 观察分析联合应用阿瑞匹坦、盐酸托烷司琼、地塞米松二级预防乳腺癌术后蒽环类药物联合环磷酰胺（AC方案）化疗所致恶心呕吐的疗效及不良反应。 方法 选取2015年1月至2016年5月在山东省德州市市立医院肿瘤科住院治疗的乳腺癌术后AC方案首次化疗相关性恶心呕吐（chemotherapy-induced nausea and vomiting，CINV）为中重度的患者72例，随机分为观察组35例，对照组37例。继续化疗过程中，观察组使用阿瑞匹坦+盐酸托烷司琼+地塞米松三联止吐药物预防CINV，对照组使用盐酸托烷司琼+地塞米松预防CINV。观察两组患者化疗后急性期（0~24 h）及延迟期（24~120 h）预防恶心呕吐的效果及不良反应发生情况。 结果 两组患者急性期呕吐的完全控制率比较，差异无统计学意义（P>0.05），观察组急性期呕吐的有效控制率较对照组明显升高，差异有统计学意义（P<0.05）；观察组延迟期呕吐的完全控制率及有效控制率均高于对照组，差异均有统计学意义（P<0.05）。两组患者不良反应主要为便秘、疲乏、面色潮红、焦虑及头晕等，均症状轻微。 结论 对乳腺癌AC方案化疗后中重度呕吐患者，化疗过程中给予阿瑞匹坦三联止吐治疗效果好，经济效益较高，且不良反应轻微，患者可耐受。

English Abstract

齐婧. 阿瑞匹坦对乳腺癌AC方案化疗后中重度呕吐患者的二级预防[J]. 药学实践与服务, 2017, 35(2): 158-160,181. doi: 10.3969/j.issn.1006-0111.2017.02.015
引用本文: 齐婧. 阿瑞匹坦对乳腺癌AC方案化疗后中重度呕吐患者的二级预防[J]. 药学实践与服务, 2017, 35(2): 158-160,181. doi: 10.3969/j.issn.1006-0111.2017.02.015
shu
QI Jing. The secondary prevention of aprepitant in moderate-severe vomiting caused by AC chemotherapy on breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 158-160,181. doi: 10.3969/j.issn.1006-0111.2017.02.015
Citation: QI Jing. The secondary prevention of aprepitant in moderate-severe vomiting caused by AC chemotherapy on breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 158-160,181. doi: 10.3969/j.issn.1006-0111.2017.02.015
shu

    全文HTML

参考文献 (9)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计